FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
What happened
In December 2025, FDA reviewed NewSelf's website at https://www.newself.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said the pictured labels identify NewSelf in a way that suggests NewSelf is the company that makes the drugs when it is not. FDA also said website claims such as “Same active ingredient as Ozempic® & Wegovy®” and “What is the FDA-approved use of Wegovy?” falsely imply FDA approval or evaluation.
What FDA found
The website label shows “NewSelf” as if NewSelf made the compounded semaglutide and tirzepatide products, but FDA says it is not the company that makes them, so the labeling is misbranded (false or misleading).
FDCA §502(a) [21 U.S.C. §352(a)]; §502(bb) [21 U.S.C. §352(bb)]; 21 CFR §201.1(h)(2)Claims that the products have the “same active ingredient” as Ozempic, Wegovy, Mounjaro, or Zepbound imply FDA approval or evaluation that these compounded drugs do not have, so the claims are misbranded.
FDCA §502(a) [21 U.S.C. §352(a)]; §502(bb) [21 U.S.C. §352(bb)]Website questions about the “FDA-approved use” of Wegovy and Zepbound imply NewSelf's compounded products are FDA-approved when they are not, so the claims are misbranded.
FDCA §502(a) [21 U.S.C. §352(a)]; §502(bb) [21 U.S.C. §352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA §301(a) [21 U.S.C. §331(a)]Receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is also prohibited.
FDCA §301(c) [21 U.S.C. §331(c)]
What FDA wants
Within 15 working days of receipt, send a written response to CDER's Office of Compounding Quality and Compliance describing steps taken to address the violations. Include the entities that produce the compounded products, sample labeling, and the basis for other website claims or evidence they were changed or removed.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- pharmacies whose compounded drugs are advertised by telehealth sites
- marketers making FDA-approval or brand-name comparison claims
This is a summary. Read the original letter on fda.gov.